Chemistry:Eflapegrastim
From HandWiki
| Identifiers | |
|---|---|
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
Eflapegrastim (HM-10460A) is a long acting G-CSF analog developed by Hanmi Pharmaceutical and licensed to Spectrum Pharmaceuticals. It was developed for the treatment of chemotherapy-induced neutropenia.[1]
It is in phase III clinical trials comparing the efficacy to that of pegfilgrastim in patients with breast cancer.[2]
References
- ↑ pharmaceutical, hanmi. "Pipeline - R&D". http://www.hanmipharm.com/ehanmi/handler/Rnd-Pipeline.
- ↑ "RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide - Full Text View - ClinicalTrials.gov". https://clinicaltrials.gov/ct2/show/NCT02643420.
 |
